A Transmed fornece soluções de PIB da primeira à última milha para o transporte farmacêutico na Alemanha

The company

Headquartered in Regensberg, Germany, transmed Transport GmbH specializes in the distribution of drugs and healthcare products to pharmacies, dispensing doctors, hospitals, medical centers, and care homes.

Transmed is the logistics and transport arm of the PHOENIX Group, Europe’s leading pharmaceutical wholesaler, with annual revenues of EUR 23.3bn as at 31/1/16 from operations in 26 countries.

Active across West, Central, East, and South East Europe, PHOENIX serves around 60,000 customers, supplying up to 140,000 different pharmaceutical items from its network of 153 distribution centers.

In its home market of Germany, transmed operates from three main temperature-controlled warehouse hubs, serving 20 regional DCs. Its fleet of 2,500 vehicles delivers goods around the clock both for its parent company and, more recently, under direct contract to pharmaceutical producers.

The fleet ranges from the smallest caddy vehicles for local “milk run” deliveries up to two hours; to mid-range vans up to 2.8 tons for longer-range operations; to temperature-controlled vans up to 3.5 tons for the longest distances, including overnight deliveries up to 1,000 km and more.

The challenge

In September 2013, the EU introduced its revised Good Distribution Practice (GDP) Guidelines (2013/C 343/01), aimed at maintaining the quality and integrity of medicinal products for human use right along the supply chain from manufacturer to patient.

The updated guidelines recognized the increasingly complex, multi-party nature of modern pharmaceutical distribution networks and sought to provide a new framework for risk management and quality control.

In particular, the 2013 Guidelines laid down new rules for transport, to protect medicinal products against breakage, adulteration, and theft and, critically, “to ensure that temperature conditions are maintained within acceptable limits during transport.”

“This new stipulation for temperatures to be maintained and validated across the transport chain was a game-changer for pharmaceutical shippers and carriers alike,” says Stefan Butenholz, Regional Manager North for transmed.

As the German government moved to enact the new guidelines into national law, transmed initiated dialogue with the authorities and carried out extensive tests to measure temperatures throughout its transport and storage operations, to understand what it needed to do, and change, to respond to the new rules.

Along the way, it identified “a chance to provide GDP-compliant solutions direct to pharmaceutical manufacturers, not just to our mother company,” says Butenholz.

Setting up the new GDP-compliant solutions required investment in refrigerated and air-conditioned vehicles and revised operating processes for warehouse hubs and regional DCs.

But to meet the needs of its parent company, and to go direct to pharmaceutical producers with an offer to fulfil their GDP delivery needs, it was also “crucial to provide temperature data to clients,” notes Butenholz.

The company therefore started looking into track-and-trace technology that would allow it “to monitor and validate our temperature control protocols both in transport and storage operations.”

VIACHAIN’s Euroscan cold chain monitoring sensors, devices, and solutions had a market-leading reputation, notes Butenholz, and transmed approached the company to explore the possibilities.